Qualigen Therapeutics’ Partner NanoSynex to Present Industry-Changing Technology at BioMed Israel
Qualigen Therapeutics, Inc. recently announced NanoSynex Ltd, a company with whom Qualigen recently entered into definitive agreements to acquire a majority stake, will be featured at BioMed Israel on May 11, 2022. BioMed Israel at David InterContinental Hotel in Tel Aviv May 10-12, 2022.
Michael Poirier, Qualigen’s Chairman and CEO, said “The prestigious opportunity provided to NanoSynex is based on their innovation and dedication to develop what we believe may become an industry-changing technology. This recognition supports Qualigen’s interest to invest in NanoSynex, and we are looking forward to collaborating with their formidable team to help develop and commercialize this potentially life-saving technology.”
NanoSynex’s innovative technology is an Antimicrobial Susceptibility Testing (AST) platform that aims to provide clinical laboratories worldwide with a rapid, accurate, and personalized test for bacterial infections, with the goal of quickly matching the correct antibiotics to treat a patient’s particular infection. Antibiotic misuse and overuse have given rise to antibiotic resistant bacteria, commonly known as superbugs, which the World Health Organization has called one of the top 10 global public health threats facing humanity. NanoSynex’s potentially game-changing AST platform aims to enable better targeting of antibiotics to ultimately result in faster and more efficacious treatment, hence reducing hospitals mortality and morbidity rates.
One of the highlights of the Biomed Israel 2022 Exhibition is the Start-Up Pavilion, dedicated to providing a highly respected platform for innovative companies to maximize exposure and partnering opportunities. Strategically located in the Israel Innovation Authority Pavilion, this integral space is a focal point for visits from local and overseas delegations and individuals, consisting of potential collaborators, partners, and investors.
“We are honored and privileged to be featured at Biomed Israel 2022, the foremost international life science conference in Israel. The Start-Up Pavilion provides the greatest opportunity to further our key partnerships, and to put a spotlight on the critical need to dramatically accelerate and personalize the diagnostic process through revolutionary AST,” added NanoSynex Co-Founder and Chief Executive Officer, Diane Abensur Bessin.
Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer, as well as maintaining and expanding its core FDA-cleared FastPack System, which has been used successfully in diagnostics for over 20 years. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may thereby be able to inhibit the cells’ proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML). The investigational compounds within Qualigen’s RAS-F family of RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers. In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions. For more information, visit www.qualigeninc.com.
NanoSynex is a MedTech company that aims at providing new solutions to improve testing quality, patient outcomes, and reduce healthcare costs by speeding up diagnostic processes. NanoSynex is focused on the development and commercialization of a rapid innovative Antimicrobial Susceptibility Test (AST). The technology is based on a purely phenotypic approach and uses a microfluidic disposable test card platform and method that optimizes bacterial growth. This disruptive development was born from exciting research discoveries at the lab of Professor Shulamit Levenberg, former Dean of the Technion Institute of Technology – Biomedical Engineering Faculty. For more information, visit www.nanosynex.com.
Total Page Views: 166